European Protein Degradation Congress 2020 | Kisaco Research

Progressing translation of protein degradation probes into safe, effective therapeutics.

First Speakers Confirmed for Europe 2020 Congress

Download Agenda
Basel, Switzerland
12-13 May, 2020

Interested in the North American Protein Degradation Congress, San Diego, 4-6 February 2020?

“A lot of data on PROTAC research has been disclosed on this event. And also many leaders in PROTAC shared their experience and concerns about PROTAC development. Many start up companies also delivered their progress. We can discuss future PROTAC directions as well as difficulties with experts from both industry and the academic area, and learned a lot. ”

Yuqing Huang - CFO, Kintor

2020 Confirmed Speakers

Phil Chamberlain

Senior Director, Structural and Chemical Biology
Celgene

Eric Fischer

Assistant Professor of Biological Chemistry and Molecular Pharmacology
Harvard Medical School

Alessio Ciulli

Professor of Chemical & Structural Biology
University of Dundee Division of Biological Chemistry and Drug Discovery

Gwenn Hansen

Vice President of Drug Discovery Technologies
Nurix Therapeutics

Why Attend

“Targeted protein degradation promises to be the greatest innovation in small molecule drug discovery in the new millennium.” - Manfred Koegl, Lab Head Oncology Research, Boehringer Ingelheim

With capital investment coming in fast, industry is ready to commercialise the therapeutic potential of PROTACs and molecular glues to build safe, effective targeted protein degradation products. As Arvinas conducts the groundbreaking first PROTAC clinical trials this year, it could be only be a matter of time before PROTACs and molecular glues enter the market. 

The European Protein Degradation Congress will bring together leading industry players within big pharma and biotech along with expert academics in the ubiquitin space - providing an open forum and facilitate the sharing of in vitro and in vivo data, as well as build a deeper mechanistic understanding of the ubiquitin pathways and techniques to make the ‘undruggable’ druggable.

Expect to hear strategies to overcome the structural biology, pharmacology and chemistry obstacles associated with the discovery and development of these bi-functional and single entity molecules.

200+
Attendees
24+
Leading Speakers
2
Days of sharing the latest developments

Previous Attendees Include

highlights from 2019

Protein degradation Congress

Talk to our speakers about...

1. How to exploit protein homeostasis to identify new proteins for degradation

2. How to find new E3 ligase recruiters

3. What does the next generation of targeted protein degradation products look like?

4. How can chemo-proteomics be used to make the ‘undruggable’ druggable?

5. Structural-based design of PROTAC through crystallography techniques

6. Furthering our understanding of the ubiquitin space.

7. New synthetic molecular glue approaches from auxin scaffolds

8. How mechanistic understanding of the DUBs space is applicable to targeted protein degradation

9. How well do PROTACs work in clinical application – insights into the first human trial

10. Key medicinal chemical considerations for moving from a PROTAC/molecular glue probe to drug

Audience Breakdown

What attendees say

Speakers

 

Alessio Ciulli

Professor of Chemical & Structural Biology
University of Dundee Division of Biological Chemistry and Drug Discovery

Alessio Ciulli

Professor of Chemical & Structural Biology
University of Dundee Division of Biological Chemistry and Drug Discovery

Alessio Ciulli

Professor of Chemical & Structural Biology
University of Dundee Division of Biological Chemistry and Drug Discovery
 

Andreas Martin

Associate Professor of Biochemistry, Biophysics and Structural Biology
University of California

Andreas Martin

Associate Professor of Biochemistry, Biophysics and Structural Biology
University of California

Andreas Martin

Associate Professor of Biochemistry, Biophysics and Structural Biology
University of California
 

Claudio Joazeiro

ZMBH Research Group Leader
University of Heidelberg

Broadly we are interested in the E3 ubiquitin ligases –their biological functions, mechanism of action, and roles in disease. For the past few years, we have focused on the problem of how cells know when its proteins are aberrant or damaged, and then decide on ways to either correct or eliminate them. Protein quality control is critical to ensure proteome integrity and cellular fitness; further underscoring its relevance, defective protein quality control is a hallmark of neurodegenerative diseases.

Claudio Joazeiro

ZMBH Research Group Leader
University of Heidelberg

Claudio Joazeiro

ZMBH Research Group Leader
University of Heidelberg

Broadly we are interested in the E3 ubiquitin ligases –their biological functions, mechanism of action, and roles in disease. For the past few years, we have focused on the problem of how cells know when its proteins are aberrant or damaged, and then decide on ways to either correct or eliminate them. Protein quality control is critical to ensure proteome integrity and cellular fitness; further underscoring its relevance, defective protein quality control is a hallmark of neurodegenerative diseases.

In eukaryotic organisms, key factors conferring specificity to protein quality control are molecular chaperones and E3 ligases. We have recently discovered a novel protein quality control mechanism mediated by an E3 ligase, Listerin/Ltn1, and which takes place on ribosomes. We now know that Listerin functions as a subunit of the Ribosome-Associated Quality Control (RQC) complex, which is conserved from yeast to humans. Of relevance, Listerin mutation causes motor neuron degeneration in mice.

We employ diverse model systems and approaches to elucidate how RQC-mediated quality control occurs at the cellular and molecular levels, including biochemistry, yeast genetics, cell biology, mouse models of neurodegeneration, and structural biology. We also analyze patients’ genomes to identify mutations that affect protein quality control; these studies are leading to insights onto the molecular basis of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, and to potential therapeutic targets.

In addition to the projects on Listerin, we have been working to elucidate the functions and mechanisms of the mitochondria-anchored E3 ligase, MULAN/MUL1, and to develop small molecule inhibitors of E3 ligases that can be used as oncology therapeutics.

 

Gwenn Hansen

Vice President of Drug Discovery Technologies
Nurix Therapeutics

Gwenn is Vice President of Drug Discovery Technologies at Nurix Therapeutics, a company focused on discovering and developing next-generation therapies that target protein homeostasis through modulation of the ubiquitin proteasome system. Since joining Nurix in January of 2016, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery, and now leads teams of scientists in both early discovery as well as medicinal chemistry.

Gwenn Hansen

Vice President of Drug Discovery Technologies
Nurix Therapeutics

Gwenn Hansen

Vice President of Drug Discovery Technologies
Nurix Therapeutics

Gwenn is Vice President of Drug Discovery Technologies at Nurix Therapeutics, a company focused on discovering and developing next-generation therapies that target protein homeostasis through modulation of the ubiquitin proteasome system. Since joining Nurix in January of 2016, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery, and now leads teams of scientists in both early discovery as well as medicinal chemistry. Prior to joining Nurix, Gwenn spent one year as an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and over 13 years in a variety of discovery-focused roles at Lexicon Pharmaceuticals, both located in Houston, Texas.  Gwenn received her PhD in Biomedical Sciences from Oak Ridge National Laboratory in 1998 and completed postdoctoral training at MD Anderson Cancer Center. 

 

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.

 

Marjeta Urh

Director of Research
Promega

My role as Director in R&D at Promega is to develop novel technologies and research tools for analysis of nucleic acids and protein function. The breadth of technologies developed in my group span mass spectrometry, novel immunoassays, analysis of protein-protein and protein-small molecule interactions and targeted protein degradation. In addition, my group is involved in developing applications of Promega core technologies such as HaloTag, NanoBRET, NanoBiT and HiBiT technologies.

Marjeta Urh

Director of Research
Promega

Marjeta Urh

Director of Research
Promega

My role as Director in R&D at Promega is to develop novel technologies and research tools for analysis of nucleic acids and protein function. The breadth of technologies developed in my group span mass spectrometry, novel immunoassays, analysis of protein-protein and protein-small molecule interactions and targeted protein degradation. In addition, my group is involved in developing applications of Promega core technologies such as HaloTag, NanoBRET, NanoBiT and HiBiT technologies.

 

Markus Quessier

Scientific Leader
GSK

Markus Quessier

Scientific Leader
GSK

Markus Quessier

Scientific Leader
GSK
 

Nico Thoma

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

Nico Thoma

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

Nico Thoma

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research
 

Phil Chamberlain

Senior Director, Structural and Chemical Biology
Celgene

Phil Chamberlain obtained his BA and D.Phil. degrees from the University of Oxford before traveling to the U.S. to perform his post-doctoral work at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego. Phil joined Celgene, San Diego in 2007 and leads the Structural and Chemical Biology department which provides structural, biochemical and cellular data in support of drug discovery projects.

Phil Chamberlain

Senior Director, Structural and Chemical Biology
Celgene

Phil Chamberlain

Senior Director, Structural and Chemical Biology
Celgene

Phil Chamberlain obtained his BA and D.Phil. degrees from the University of Oxford before traveling to the U.S. to perform his post-doctoral work at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego. Phil joined Celgene, San Diego in 2007 and leads the Structural and Chemical Biology department which provides structural, biochemical and cellular data in support of drug discovery projects. Phil is known for his work in understanding and extending the action of cereblon modulators, and has published work in this area in journals including Nature and Nature Structural and Molecular Biology.

 

Radoslaw Nowak

Research Fellow
Dana-Farber Cancer Institute

Radoslaw Nowak

Research Fellow
Dana-Farber Cancer Institute

Radoslaw Nowak

Research Fellow
Dana-Farber Cancer Institute
 

Laura Itzhaki

Professor of Structural Pharmacology
University of Cambridge

Laura Itzhaki

Professor of Structural Pharmacology
University of Cambridge

Laura Itzhaki

Professor of Structural Pharmacology
University of Cambridge
 

Xavier Lucas

Computer-assisted Drug Design Scientist
Roche

Xavier Lucas

Computer-assisted Drug Design Scientist
Roche

Xavier Lucas

Computer-assisted Drug Design Scientist
Roche
 

Cristina Mayor-Ruiz

Post Doc Fellow
Georg Winter Lab

Cristina Mayor-Ruiz

Post Doc Fellow
Georg Winter Lab

Cristina Mayor-Ruiz

Post Doc Fellow
Georg Winter Lab

Expertise Partner

Event Partners

The Agenda

We are still finalisng the agenda for the Europe 2020 congress. Please download the example agenda from our Europe 2019 Congress to get a feel for the topics of discussion.

What you can expect from the 2020 congress:

  • 200+ participants from leading industry players within big pharma and biotech along with expert academics in the ubiquitin space.
  • An open forum to share the latest in vivo and in vitro data and insights and foster collaboration. 
  • 18+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
  • 2 days of progressing translation of protein degradation probes into safe, effective therapeutics.

European Protein Degradation Congress

Download Previous Agenda

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Venue

Basel, Switzerland

Venue to be confirmed

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Saturday, November 30, 2019 to Sunday, April 5, 2020
Early Bird - Service Providers
€2199 + VAT
Early Bird ends 5th April 2020. Save €300
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Saturday, November 30, 2019 to Sunday, April 5, 2020
Early Bird - Biotech + Pharma
€1699 + VAT
Early Bird ends 5th April 2020. Save €300
Must have an active drug pipeline
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Saturday, November 30, 2019 to Sunday, April 5, 2020
Early Bird - Academic
€899 + VAT
Early Bird ends 5th April 2020. Save €200
Must be a full time academic or healthcare professional
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.